Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Summary

This phase II trial tests whether oral iloprost works in preventing lung cancer (chemoprevention) in former smokers. Oral iloprost has previously been shown to reduce abnormal lung cells in former smokers, suggesting a clinically significant impact on lung cancer risk. The use of oral iloprost may help keep cancer from forming and reduce abnormal cells in the lung in order to lower the risk of developing lung cancer in former smokers.

Timeline

Start

2024-06-01

Primary completion

2026-12-01

Completion

2027-06-30

Drugs

Indications